Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081597 | 0.90 | ALOX15 (0.35) | CYP3A4CYP2D6HPGDCYP2C19GAA | |
| SCHEMBL3297420 | 0.90 | ALOX15 (0.35) | CYP3A4CYP2D6HPGDCYP2C19GAA | |
| SCHEMBL5078298 | 0.90 | ALOX15 (0.35) | CYP3A4CYP2D6HPGDCYP2C19GAA | |
| SCHEMBL3297716 | 0.81 | CYP3A4 (0.40) | CYP3A4CYP2D6CYP2C19ALDH1A1MEN1 | |
| SCHEMBL5078309 | 0.79 | POLB (0.37) | POLBOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3294327 | 0.79 | OPRM1 (0.42) | CYP3A4CYP2D6CYP2C19GAAALDH1A1 | |
| SCHEMBL5078310 | 0.79 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1HTT | |
| SCHEMBL5081532 | 0.77 | OPRM1 (0.36) | CYP3A4CYP2D6LMNAALDH1A1MEN1 | |
| SCHEMBL5082022 | 0.77 | CYP3A4 (0.37) | CYP3A4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL674830 | 0.76 | CYP2D6 (0.38) | CYP3A4CYP2D6CYP2C19ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107356-A1 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2005-05-19 | — | — | US | claimed |
| EP-1423146-A1 | COMPOSITION FOR TREATING PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT ACTIVATING DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | Aventis Pharma S.A. (FR) | 2004-06-02 | — | — | EP | claimed |
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | claimed |
| WO-2003018060-A1 | COMPOSITION FOR TREATING PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT ACTIVATING DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | AVENTIS PHARMA S.A. (FR) | 2003-03-06 | — | — | WO | claimed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | claimed |
| US-7741316-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2010-06-22 | — | — | US | disclosed |
| EP-1263720-B1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2009-06-03 | — | — | EP | disclosed |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-7148258-B2 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2006-11-16 | — | — | US | disclosed |
| US-7105504-B2 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2006-09-12 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP2D6 1341/4885HPGD 3258/4885 |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | CYP3A4 38/4885CYP2D6 7/4885HPGD 2089/4885 |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | CYP3A4 71/4885CYP2D6 38/4885HPGD 486/4885 |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP2D6 1341/4885HPGD 3258/4885 |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP2D6 1341/4885HPGD 3258/4885 |
| US-20050107356-A1 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | CNR1, CNR2, GPR18 | CYP3A4 2489/4885CYP2D6 1786/4885HPGD 930/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | CYP3A4 15/4885CYP2D6 17/4885HPGD 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.